
    
      This is a Phase 2, multicenter, randomized, double blind (masked), placebo-controlled, 2-arm
      clinical trial of 300 deceased donor kidney transplant recipients. Participants will be
      randomized (1:1) to the experimental or control arm (150 subjects per arm).
    
  